Treatment of H. pylori infection: the reality

Yale J Biol Med. 1998 Mar-Apr;71(2):119-24.

Abstract

Despite the wide dissemination of information on Helicobacter pylori, there is still a great deal of variation in how general practitioners treat the infection and in which circumstances they prescribe eradication therapy for H. pylori. Specialty societies have developed consensus guidelines that recommend a strategy to test and treat dyspeptic patients for H. pylori infection although the data to support these recommendations are weak at the present time. As a result, there is still confusion about the indications for treatment and the treatment regimens that are likely to be effective in routine clinical practice.

Publication types

  • Review

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Bacterial Agents / therapeutic use
  • Anti-Ulcer Agents / economics
  • Anti-Ulcer Agents / therapeutic use
  • Bismuth / therapeutic use
  • Clarithromycin / therapeutic use
  • Cost-Benefit Analysis
  • Drug Therapy, Combination
  • Dyspepsia / drug therapy*
  • Dyspepsia / economics
  • Dyspepsia / microbiology
  • Enzyme Inhibitors / therapeutic use
  • Guidelines as Topic
  • Helicobacter Infections / drug therapy*
  • Helicobacter Infections / economics
  • Helicobacter pylori*
  • Humans
  • Lansoprazole
  • Omeprazole / analogs & derivatives
  • Omeprazole / therapeutic use
  • Peptic Ulcer / drug therapy*
  • Peptic Ulcer / economics
  • Peptic Ulcer / microbiology
  • Primary Health Care / methods
  • Ranitidine / analogs & derivatives
  • Ranitidine / therapeutic use
  • United States
  • United States Food and Drug Administration

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Bacterial Agents
  • Anti-Ulcer Agents
  • Enzyme Inhibitors
  • Lansoprazole
  • ranitidine bismuth citrate
  • Ranitidine
  • Clarithromycin
  • Omeprazole
  • Bismuth